Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.74 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Inc (NASDAQ:AKRO) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Drive Investor Optimism ↗
Akero Therapeutics reports Q2 2025 results with narrower-than-expected loss, strong cash reserves, and promising clinical progress in MASH treatment. Stock gains 6.5% pre-market. 
Via Chartmill
News headline image
This Stock Just Doubled in 1 Day -- Is It Still a Buy? ↗
Via The Motley Fool
News headline image
Akero (AKRO) Q2 Loss Narrows 6% ↗
Via The Motley Fool
News headline image
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
AKERO THERAPEUTICS INC (NASDAQ:AKRO) - A Strong Technical Setup in Biotech ↗
AKERO THERAPEUTICS (NASDAQ:AKRO) shows strong technicals with a perfect 10 rating and a high-quality breakout setup, making it a stock to watch for traders. 
Via Chartmill
News headline image
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased ↗
Jefferies thinks big pharma companies are "still on the hunt" for deals. 
Via Stocktwits
News headline image
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Stock Rallies To 3-Month High On Buyout Report; Retail Investors Turn Bullish ↗
The company reportedly hired an investment bank to explore a possible sale. 
Via Stocktwits
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Best Biotech Stocks to Buy in 2025
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum. 
Via MarketBeat
Topics ETFs Economy Government
News headline image
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law Office
From Grabar Law Office
Via GlobeNewswire
News headline image
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is
From Grabar Law Office
Via GlobeNewswire
News headline image
The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry ↗
In this video lesson, I review the overall market and a new swing position for Monday's session. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Mid-Caps Worth Watching Closely in March
Unlike their mega-cap counterparts, which tend to grind, mid-caps can soar or crash within days, driven by headlines and pure speculation. 
Via MarketBeat
News headline image
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
News headline image
Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino’s Pizza Corp. (NASDAQ: DPZ)
From Grabar Law Office
Via GlobeNewswire
News headline image
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio? ↗
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners... 
Via Benzinga
News headline image
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Akero Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.